Skip to content
    Back to Archive

    2025 Archive

    12 articles from 2025

    FDA adopts agentic artificial intelligence in latest push to infuse AI into agency

    Author: Darren Incorvaia
    Journal: Fierce Healthcare
    Published 12 months ago

    TITLE: FDA Implements Agentic AI for Internal Operations: Implications for Regulatory Processes SUMMARY: The U.S. Food and Drug Administration (FDA) is advancing its integration of artificial intellig...

    TITLE: Adjuvant Docetaxel vs. Surveillance for Intermediate/High-Risk Prostate Cancer Post-Radiotherapy: SPCG-13 Final Survival Results SUMMARY: The SPCG-13 trial's final survival results investigated...

    TITLE: Niraparib/Abiraterone/Prednisone in mCRPC: Final OS Data from MAGNITUDE Trial SUMMARY: The final overall survival (OS) analysis from the Phase 3 MAGNITUDE trial investigated the combination of ...

    GSK's Tesaro, AnaptysBio lock horns in court over Jemperli agreement

    Author: Fraiser Kansteiner
    Journal: Fierce Biotech
    Published 12 months ago

    TITLE: Legal Dispute Emerges Between GSK's Tesaro and AnaptysBio Over PD-1 Inhibitor Jemperli (Dostarlimab) SUMMARY: A significant legal conflict has developed between GlaxoSmithKline's (GSK) subsidia...

    TITLE: FDA Approves Imetelstat for Transfusion-Dependent Anemia in Low- to Intermediate-Risk MDS SUMMARY: The US Food and Drug Administration (FDA) has approved imetelstat, a first-in-class telomerase...

    Lowering Blood Pressure, Raising Cancer Risk?: Evidence From Randomized Clinical Trials and Genetic Studies

    Author: Fahmida Mannan MBBS, MRes & Marie Pigeyre MD, PhD
    Journal: JACC: CardioOncology
    Published 12 months ago

    TITLE: Antihypertensive Therapy and Malignancy Risk: Analyzing Evidence from RCTs and Genetic Studies SUMMARY: This study published in *JACC: CardioOncology* investigates the complex relationship betw...

    TITLE: Survival Outcomes of Neoadjuvant Chemotherapy in Advanced Non-Serous Ovarian Cancer SUMMARY: This study, published in *Gynecologic Oncology*, investigates the survival impact of neoadjuvant che...

    TITLE: HER2CLIMB-02 Analysis: Tucatinib Plus T-DM1 for HER2-Positive Metastatic Breast Cancer SUMMARY: The Phase III HER2CLIMB-02 clinical trial evaluated the efficacy and safety of adding the tyrosin...

    TITLE: Industry Collaboration and FDA Approval Success in Genitourinary Malignancy Phase III Trials SUMMARY: A recent analysis published in *JCO Oncology Practice* investigates the relationship betwee...

    ROME trial Wasn't Built in a Day: The Decade-Long Journey to Randomized Evidence in Precision Oncology

    Author: V. Subbiah
    Journal: Annals of Oncology
    Published 12 months ago

    TITLE: ROME Trial Analysis: The Evolution of Randomized Evidence in Precision Oncology SUMMARY: This commentary in *Annals of Oncology* explores the critical transition from early-phase, single-arm st...

    TITLE: Para-aortic Lymphadenectomy in Locally Advanced Cervical Cancer: Impact of Lymph Node Yield (FRANCOGYN Study) SUMMARY: This publication from the European Journal of Surgical Oncology presents f...

    TITLE: Eftilagimod Alpha and Pembrolizumab in First-Line Metastatic NSCLC: TACTI-002 Study Analysis SUMMARY: Recent data published in *JCO Oncology Advances* presents findings from the TACTI-002 study...